NCT06617585

Brief Summary

circular RNAs (circRNAs), a newly discovered type of endogenous noncoding RNAs \[8\], are involved in the regulation of various biological functions. They act by sponging off certain microRNAs (miRNAs) and play a role in the pathogenesis of many diseases, including cancers \[9-11\]. In addition, circRNAs are not com- monly degraded by RNA enzymes present in body flu- ids \[8\], and most of them possess expression specificity at the tissue, cell, and developmental stage level \[12,13\]. Thus, they can be ideal clinica

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
28mo left

Started Dec 2024

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Dec 2024Oct 2028

First Submitted

Initial submission to the registry

November 27, 2023

Completed
10 months until next milestone

First Posted

Study publicly available on registry

September 27, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

December 1, 2024

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2028

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2028

Last Updated

September 27, 2024

Status Verified

September 1, 2024

Enrollment Period

3.2 years

First QC Date

November 27, 2023

Last Update Submit

September 26, 2024

Conditions

Ovarian Cancer

Outcome Measures

Primary Outcomes (1)

  • role of circDENND4c in the diagnosis of ovarian cancer

    by quality real time PCR we use the circDENND4c as a tumour marker for ovarian cancer

    baseline

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

apparently healthy group and group of known diagnosed as ovary cancer in assiut uni hospital

You may qualify if:

  • \- patients at South Egypt Cancer institute and Recently diagnosed ovarian cancer patients 2. Patients not went to surgery.

You may not qualify if:

  • Patients receive any anti-cancer therapy. 2. Patients diagnosed with other concomitante cancer or chronic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Serum samples

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Central Study Contacts

Marwa MamDouh Mohamed

CONTACT

20+1153538300marwaamamdouh26@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

November 27, 2023

First Posted

September 27, 2024

Study Start

December 1, 2024

Primary Completion (Estimated)

February 2, 2028

Study Completion (Estimated)

October 1, 2028

Last Updated

September 27, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share